Health Care Predictions for 2024

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

The HIV vaccine field has recently faced setbacks with trials like PrepVacc, Mosaico and Imbokodo ending early due to lack of preventive efficacy. Although there have been challenges, scientists have made discoveries showing that the immune system can be prepared to fight HIV with special antibodies.

In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.

Duvyzat was approved in March 2024 and works to reduce the inflammation and loss of muscle experienced by patients with Duchenne muscular dystrophy.

A substudy of the FLAIR phase 3 trial found that participants favored intramuscular injection of Cabenuva over the subcutaneous version due to pain and the development of nodules and reddening of the skin.